The ATG5 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung carcinoma epithelial cell line A-549. This product features targeted disruption of the ATG5 gene, a central autophagy component. The polyclonal format yields a heterogeneous ATG5-null population, minimizing clonal artifacts and enabling robust functional studies in an established lung adenocarcinoma background.
A-549 cells were established from lung adenocarcinoma tissue of a 58-year-old Caucasian male and are widely employed for lung cancer research and drug screening. As a type II alveolar epithelial-derived line, A-549 possesses KRAS and STK11 mutations and exhibits intrinsic chemoresistance. This genetic backdrop makes it valuable for examining tumor survival mechanisms, particularly those involving autophagy.
ATG5 is essential for autophagosome formation via covalent conjugation with ATG12, facilitated by ATG7 and ATG10. The ATG5-ATG12 conjugate interacts with ATG16L1 and TECPR1 to form a complex that promotes LC3 lipidation, phagophore elongation, and autophagosome completion. Upstream, ATG5 is negatively regulated by mTORC1 and positively by AMPK and ULK1 during nutrient deprivation. Downstream, this conjugation system enables LC3-mediated cargo recruitment, p62/SQSTM1 degradation, and autolysosome formation. CRISPR/Cas9-mediated ATG5 disruption ablates canonical macroautophagy, causing accumulation of damaged organelles and protein aggregates, and sensitizing cells to stress-induced apoptosis.
In A-549 lung adenocarcinoma cells, autophagy often supports chemoresistance and survival under stress. ATG5 knockout provides a loss-of-function model to dissect autophagy??s role in tumor biology, including apoptosis crosstalk and chemosensitivity. Standard validation assays include Western blotting for LC3-II/I ratio and p62 turnover, LC3 puncta immunofluorescence, and autophagy flux assays with chloroquine. This model further enables analysis of migration, invasion, and clonogenic growth, offering a comprehensive platform for oncology research.
This polyclonal ATG5 knockout cell product suits diverse applications: studying autophagy-dependent survival signaling, synthetic lethality screens with targeted drugs or proteasome inhibitors, and investigations of autophagy in the tumor microenvironment. It is also applicable to SARS-CoV-2 infection studies. Representative assays encompass RT-qPCR for ATG5 mRNA, flow cytometry for apoptosis, and drug sensitivity profiling with combination treatments such as cisplatin. For further technical information or inquiries, please contact Ascent Research.
